Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: The WECARE Study Group

Journal of Clinical Oncology

Volumn 26, Issue 9, 2008, Pages 1411-1418

  Figueiredo, Jane C ^a   Bernstein, Leslie ^a   Capanu, Marinela ^a   Malone, Kathleen E ^a   Lynch, Charles F ^a   Anton Culver, Hoda ^a   Stovall, Marilyn ^a   Bertelsen, Lisbeth ^a   Haile, Robert W ^a   Bernstein, Jonine L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; SEX HORMONE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER; AGED; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DENMARK; ETHNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRE; REGISTER; RISK; RISK ASSESSMENT; STATISTICAL MODEL; UNITED STATES;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, HORMONAL; DENMARK; FEMALE; GONADAL STEROID HORMONES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; POSTMENOPAUSE; QUESTIONNAIRES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 41149122115     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.3081     Document Type: Article

References (26)

1. US Food and Drug Administration: Medical product safety information. http://www.fda.gov/medwatch/SAFETY/2005/safety.htm
2. Horn PL, Thompson WD: Risk of contralateral breast cancer: Associations with histologic, clinical, and therapeutic factors. Cancer 62:412-424, 1988
3. Bernstein JL, Thompson WD, Risch N, et al: Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 136:925-936, 1992
4. Trentham-Dietz A, Newcomb PA, Nichols HB, et al: Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat 105:195-207, 2007
5. Li CI, Malone KE, Porter PL, et al: Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 89:513-518, 2003
6. Marchbanks PA, McDonald JA, Wilson HG, et al: Oral contraceptives and the risk of breast cancer. N Engl J Med 346:2025-2032, 2002
7. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies: Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347:1713-1727, 1996
8. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
9. Beral V: Breast cancer and hormonere-placement therapy in the Million Women Study. Lancet 362:419-427, 2003
10. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer - Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350:1047-1059, 1997
11. Lee SA, Ross RK, Pike MC: An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049-2058, 2005
12. Solomon CG, Dluhy RG: Rethinking postmenopausal hormone therapy. N Engl J Med 348:579-580, 2003
13. Holmberg L, Anderson H: HABITS (Hormonal Replacement Therapy After Breast Cancer - Is It Safe?), a randomised comparison: Trial stopped. Lancet 363:453-455, 2004
14. von Schoultz E, Rutqvist LE: Menopausal hormone therapy after breast cancer: The Stockholm randomized trial. J Natl Cancer Inst 97:533-535, 2005
15. Powles TJ, Hickish T, Casey S, et al: Hormone replacement after breast cancer. Lancet 342:60-61, 1993
16. DiSaia PJ, Grosen EA, Kurosaki T, et al: Hormone replacement therapy in breast cancer survivors: A cohort study. Am J Obstet Gynecol 174:1494-1498, 1996
17. O'Meara ES, Rossing MA, Daling JR, et al: Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93:754-762, 2001
18. Xydakis AM, Sakkas EG, Mastorakos G: Hormone replacement therapy in breast cancer survivors. Ann N Y Acad Sci 1092:349-360, 2006
19. Bernstein JL, Langholz B, Haile RW, et al: Study design: Evaluating gene-environment interactions in the etiology of breast cancer-The WECARE Study. Breast Cancer Res 6:R199-214, 2004
20. Langholz B: Counter-matching, in Armitage P, Colton T (eds): Encyclopedia of Biostatistics (ed 2). New York, NY, John Wiley, 2005, pp 1248-1254
21. Huberman M, Langholz B: Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epidemiol 150:1340-1345, 1999
22. Wu A, Pearce CL, Spicer DV, et al: Body weight, menopausal hormone therapy, and risk of breast cancer, in Lobo RA (ed): Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. New York, Raven Press Ltd, 2007
23. Rosenberg LU, Einarsdottir K, Friman EI, et al: Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:2482-2488, 2006
24. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
25. Narod SA, Dube MP, Klijn J, et al: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773-1779, 2002
26. Haile RW, Thomas DC, McGuire V, et al: BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 15:1863-1870, 2006